JPMorgan Chase & Co. Purchases 127,513 Shares of Generation Bio Co. (NASDAQ:GBIO)

JPMorgan Chase & Co. raised its position in Generation Bio Co. (NASDAQ:GBIO) by 74.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 297,705 shares of the company’s stock after purchasing an additional 127,513 shares during the period. JPMorgan Chase & Co. owned 0.45% of Generation Bio worth $316,000 at the end of the most recent reporting period.

Separately, Barclays PLC raised its stake in Generation Bio by 165.5% in the third quarter. Barclays PLC now owns 76,430 shares of the company’s stock valued at $189,000 after purchasing an additional 47,639 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Stock Performance

GBIO stock opened at $0.44 on Friday. The company has a market capitalization of $29.21 million, a PE ratio of -0.20 and a beta of 2.78. Generation Bio Co. has a one year low of $0.32 and a one year high of $4.34. The company’s 50 day moving average price is $0.45 and its two-hundred day moving average price is $1.01.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Wednesday, March 19th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Generation Bio had a negative net margin of 782.86% and a negative return on equity of 104.85%. The business had revenue of $4.19 million for the quarter, compared to the consensus estimate of $2.92 million. On average, research analysts predict that Generation Bio Co. will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of Generation Bio in a report on Friday, March 14th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Generation Bio in a research note on Thursday, April 10th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $9.00 price target on shares of Generation Bio in a research report on Monday, March 17th.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.